0040 GMT - National Australia Bank's sale of its remaining stake in MLC Life Insurance is unlikely to have any impact on key investment decisions at the lender, Morgan Stanley analyst Richard E. Wiles says. He writes in a note that the A$500 million sale of the 20% stake to Japan's Nippon Life is consistent with NAB's strategy and will have no material impact on cash earnings. Wiles reckons that the sale will lift NAB's CET 1 capital ratio to a pro-forma 12.3%, implying A$3.4 billion of excess capital. He assumes that NAB will dedicate A$3 billion of this to further share buybacks. MS has an overweight rating and an A$38.40 target price on the stock, which is up 0.1% at A$37.64. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
December 11, 2024 19:40 ET (00:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.